Expanding CGMP Facilities to Meet Heightened Demand for Plasmid DNA Based Vaccine TherapeuticsExpanding CGMP Facilities to Meet Heightened Demand for Plasmid DNA Based Vaccine Therapeutics
SLASH TIME FROM BENCH TO BEDSIDE: Cutting-edge biomanufacturing for mAbs, vaccines, and advanced therapies. Bright ideas, bold science, and big innovations—delivering efficiency, precision, and quality through every phase of bioprocessing.